SCHEMBL22976542

SCHEMBL22976542

O=Cc1cnc(Cl)c(Br)c1N1CC[C@H](NC(=O)O)C1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AURKA O14965 2/20 0.37
▸ AURKB Q96GD4 2/20 0.37
▸ SMPD3 Q9NY59 1/20 0.36
▸ OPRK1 P41145 2/20 0.36
▸ BTK Q06187 2/20 0.34
▸ JAK3 P52333 2/20 0.34
▸ TRPV1 Q8NER1 3/20 0.33
▸ AKT1 P31749 1/20 0.33
▸ TRPM8 Q7Z2W7 1/20 0.33
▸ CA12 O43570 4/20 0.33
▸ CA1 P00915 4/20 0.33
▸ CA2 P00918 4/20 0.33
▸ CA4 P22748 4/20 0.33
▸ CA7 P43166 4/20 0.33
▸ CA9 Q16790 4/20 0.33
▸ CCNC P24863 1/20 0.33
▸ CDK8 P49336 1/20 0.33
▸ ACKR3 P25106 1/20 0.33
▸ DRD2 P14416 1/20 0.33
▸ DRD4 P21917 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22976543 1.00 AURKA (0.37) AURKAAURKBSMPD3OPRK1BTK
SCHEMBL29653516 0.84 JAK3 (0.49) BTKJAK3
SCHEMBL28777527 0.84 JAK3 (0.49) BTKJAK3
SCHEMBL28777529 0.84 JAK3 (0.49) BTKJAK3
SCHEMBL21248811 0.81 SMPD3 (0.35) SMPD3OPRK1BTKJAK3TRPV1
SCHEMBL21248810 0.81 SMPD3 (0.35) SMPD3OPRK1BTKJAK3TRPV1
SCHEMBL22976844 0.81 SMPD3 (0.35) AURKAAURKBSMPD3BTKCA12
SCHEMBL22976842 0.81 SMPD3 (0.35) AURKAAURKBSMPD3BTKCA12
SCHEMBL28777659 0.78 HRH3 (0.34) OPRK1
SCHEMBL28777662 0.78 HRH3 (0.34) OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4294797-A1 CRYSTALLINE FORMS OF A SOMATOSTATIN MODULATOR Crinetics Pharmaceuticals, Inc. (US) 2023-12-27 — — EP disclosed
CN-117043149-A Crystalline forms of somatostatin modulators 克林提克斯医药股份有限公司 2023-11-10 — — CN disclosed
US-11773076-B2 Crystalline forms of a somatostatin modulator Crinetics Pharmaceuticals, Inc. (US) 2023-10-03 — — US disclosed
WO-2022177974-A1 CRYSTALLINE FORMS OF A SOMATOSTATIN MODULATOR Crinetics Pharmaceuticals, Inc. (US) 2022-08-25 — — WO disclosed
EP-4013748-A1 NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. (US) 2022-06-22 — — EP disclosed
US-20220144802-A1 NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2022-05-12 — — US disclosed
WO-2021030262-A1 NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. (US) 2021-02-18 — — WO disclosed
US-20210047287-A1 NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2021-02-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220144802-A1 NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF SSTR5, SSTR4, SSTR3 AURKA 4854/4885AURKB 4797/4885SMPD3 312/4885
US-20210047287-A1 NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF SSTR5, SSTR4, SSTR3 AURKA 4854/4885AURKB 4797/4885SMPD3 312/4885
US-11773076-B2 Crystalline forms of a somatostatin modulator SSTR5, SSTR3, SSTR4 AURKA 3831/4885AURKB 4357/4885SMPD3 665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback